Arvinas rises on FDA's 'fast track' tag for breast cancer therapy

Arvinas

06/02/2024 13:44

** Shares of drug developer Arvinas  ARVN.O  rise 3.5% to
$47.9 premarket 
    ** Co announces that U.S. FDA has granted its experimental
breast cancer therapy, jointly developed with Pfizer  PFE.N 
"fast track" designation 
    ** FDA's "fast track" designation is intended to expedite
the review of drug candidates being developed to treat serious
conditions
     ** The experimental therapy known as vepdegestrant is being
studied as a monotherapy in an ongoing late-stage study in
previously treated patients with a type of breast cancer
    ** Stock rose 30.8% in the last 12 months 
    

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))